Rigel Pharmaceuticals (NASDAQ: RIGL) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Rigel Pharmaceuticals to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

88.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.2% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Rigel Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals 0 0 4 0 3.00
Rigel Pharmaceuticals Competitors 1370 4438 12229 310 2.63

Rigel Pharmaceuticals currently has a consensus price target of $6.75, indicating a potential upside of 177.21%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.83%. Given Rigel Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Rigel Pharmaceuticals is more favorable than its peers.


This table compares Rigel Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals -354.14% -105.86% -82.23%
Rigel Pharmaceuticals Competitors -4,722.05% -356.12% -43.37%

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals’ peers have a beta of 6.60, suggesting that their average share price is 560% more volatile than the S&P 500.

Earnings and Valuation

This table compares Rigel Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Rigel Pharmaceuticals $10.34 million -$67.71 million -3.53
Rigel Pharmaceuticals Competitors $470.18 million $170.66 million -6.51

Rigel Pharmaceuticals’ peers have higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.